Journal of Clinical Oncology, Vol 26, No 17 (June 10), 2008: pp. 2828-2838
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2008.17.6941
Human Colon Cancer Stem Cells: A New Paradigm in Gastrointestinal Oncology
Bruce M. Boman,
Emina Huang
From the Helen F. Graham Cancer Center, Newark, DE; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA; and the Department of Surgery, University of Florida, Gainesville, FL
Corresponding author: Bruce M. Boman, MD, PhD, Helen Graham Cancer Center, Christiana Care Health System, 4701 Ogletown-Stanton Rd, Newark, DE 19713; e-mail: bruce.boman{at}mail.tju.edu
For the past half century, oncologists have had systemic drugs available, agents that are able to induce tumor responses in patients with colorectal cancer. However, in cases of advanced colorectal cancer, these regimens are almost never curative. The recently introduced concept that cancer stem cells (SCs) drive tumor growth suggests a reason for these therapeutic failures— current chemotherapeutics target rapidly dividing cells but cancer SCs divide only slowly, and, they are relatively resistant to cytotoxic systemic therapies. It also suggests a solution—development of therapeutics that target cancer SCs. However, there is a paucity of information about the mechanisms by which SC populations are maintained and about the mechanisms by which tumor SCs are involved in colon cancer development. In this article, we discuss these mechanisms and recent developments in the identification and isolation of colon cancer SCs using new SC markers. We then discuss the role of SCs in homeostasis of normal colonic epithelium, and mechanisms by which dysregulation of crypt mechanisms can lead to initiation and progression of colon cancer. Our hypothesis, which has received recent experimental support, is that the mechanism that links abnormalities at the gene level (eg, APC mutations) and abnormalities at the tissue level (eg, proliferative shift, dysplasia, carcinoma) from cancer initiation to metastasis is SC overpopulation. Finally, we discuss the concept that symmetric cancer SC division is an essential mechanism that drives tumor growth, and that development of a new generation of therapeutics that target colon cancer SCs by inhibiting symmetric SC division holds promise for truly curative approaches for patients with advanced colorectal cancers.
Supported in part by funds from the Weatherwax Foundation, University of Michigan Comprehensive Cancer Center.
Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. Enderling, A. R.A. Anderson, M. A.J. Chaplain, A. Beheshti, L. Hlatky, and P. Hahnfeldt
Paradoxical Dependencies of Tumor Dormancy and Progression on Basic Cell Kinetics
Cancer Res.,
November 15, 2009;
69(22):
8814 - 8821.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. H. Huang, M. J. Hynes, T. Zhang, C. Ginestier, G. Dontu, H. Appelman, J. Z. Fields, M. S. Wicha, and B. M. Boman
Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon Tumorigenesis
Cancer Res.,
April 15, 2009;
69(8):
3382 - 3389.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Miele, N. Takebe, and S. P. Ivy
The Cancer Stem Cell Hypothesis, Embryonic Signaling Pathways, and Therapeutics: Targeting an Elusive Concept
ASCO Educational Book,
January 1, 2009;
2009(1):
145 - 156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. M. Boman and M. S. Wicha
Cancer Stem Cells: A Step Toward the Cure
J. Clin. Oncol.,
June 10, 2008;
26(17):
2795 - 2799.
[Full Text]
[PDF]
|
 |
|
|